Drugs Affecting the Reproductive System
Good day everyone and for this video i am going to be a metroxy progesterone it is a drug that affects the productive system so first what is hydroxyl progesterone so immunoxine progesterone is a female hormone that helps regulate ovulation and struggle periods the treat conditions such as absent or irregular menstruation and abnormal uterine bleedings we
Traveling and my generic name is hydroxy progesterone and there are four available brand names in the philippines first is defomin second is deputras third is provera and lastly provision my chemical name is my therapeutic drug classification is antenna plastic a contraceptive hormone and for pharmacologic drug classification is a hormone of protestant hormone
My mechanism of action involves inhibiting the production of gonadotropin preventing follicular maturation and ovulation thus preventing pregnancy my other action includes secretory changes in the endometrium increase in basal body temperature biological changes in vaginal epithelium relaxation of uterine muscles mammary alveolar growth and withdrawal bleeding
In the presence of estrogen i can also reduce the growth of some cancer cells by inducing p53 dependent apoptosis in certain cancer cell lines and inhibit gaba-a receptors pharmacokinetics first absorption i am rapidly absorbed through your muscular and oral administration distribution i am extensively protein bound primarily to albumin and corticosteroid
Binding globulin metabolism i have rapid mainly in liver lastly excretion i am primarily excreted through urine my half-life is 2 and 1 4 to 9 hours through oral administration and 10 weeks through intermuscular administration for indications of metroxy progesterone acetate me as an oral tablet or indicated to treat secondary amino area reduce the incidence
Of endometrial hyperplasia in post-menopausal women and to treat abnormal uterine bleeding due to hormone imbalance me as an oral doublet or indicated to prevent postmenopausal osteoporosis and to treat moderate to severe menopausal symptoms such as vasomotor symptoms vulgar atrophy and vaginal atrophy me as in subcutaneous mpa is dedicated to prevent pregnancy
And manage pain as a sharing with endometriosis me as an intravascular mpa is dedicated to prevent pregnancy and at a higher concentration for palliative treatment of endometrial or renal carcinoma i am contraindicated to pregnant women patients who are hypersensitive to me and patients with active or previous thromboembolic disorder cerebral vascular disease or
Stroke apoplexy breast cancer and diagnosed abnormal vaginal bleeding missed abortion or hepatic dysfunction tablets are contraindicated in patients with liver dysfunction known or suspected malignant disease in the genital organ use cautiously in patients with diabetes bilitis seizure migraines cardiac or renal dysfunction asthma or depression i have several
Side and adverse effects it is categorized by body system so first central nervous system it causes headache migraine dizziness mental depression career nervousness mood disturbances irritability exacerbation of epilepsy dementia astraria loturgy and stroke for eyes ears nose and throat it causes rhinovascular thrombosis and intolerance to contact lenses for a
Degreementary system it causes melasma that may persist when drug is discontinued it also causes erythema multi-form erythema medosam hemorrhagic eruption loss of scalp hair his autism paretos rush induration acne and stereo abscesses cardiovascular system edema deep and superficial venous thrombosis thromboembolism thrombophyllbytes myocardial infarction stroke
And hypertension miscellaneous hypersensitivity or allergic reactions including anaphylaxis and angioedema injection site reactions aggravation or porphyria edema arthralgia leg cramps changes in libido orthocardia angioedema anaphylactoid or anaphylactic reactions and hypokalsi for the breasts tenderness enlargement pain nipple discharge galacteria fabricistic
Breast changes breast cancer in the metabolic i can cause bone loss weight gain or weight loss reduced carbohydrate tolerance and hyperglycemia diabotic system cholestatic jaundice gallbladder disease and tumors lastly in the respiratory system i can cause pulmonary imbalance for gastrointestinal side effect it causes nausea vomiting abdominal cramps bloating
Calisthenic jaundice increased incidence of gallbladder disease procreatitis enlargement of hepatic human jones drug induced hepatitis and gingival bleeding for janitorial system it causes abnormal uterine bleeding change in menstrual flow breakthrough bleeding spotting aminaria cervical secretions nutrient fibromus vagina carcinogenesis and dysmenorrhea for
Fluid and electrolyte it may lead to edema you must take note that a nurse must be responsible in giving me as a drug metroxy progesterone to a client there are things you should do before during and after so let’s start discussing the before first is you need to monitor bp periodically during therapy second is to assess patients usual menstrual history
Administration of drug may begin of any day of cycle in patients with an area and a day 16 or 21 of cycle in patients with dysfunctional bleeding monitor intake and output ratios and weekly weight you should report significant discrepancies or study weight gain next is should consider laboratory test consideration like hepatic function before and periodically
During therapy you should assess patients or family’s knowledge about trap therapy and you should provide family teaching and lastly you need to review patient package insert with patient you should emphasize that notifying health care professionals if the following side effects occur during implementation there are nursing responsibilities during administration
And subcutaneous shake me vigorously before use to form uniform suspension inject slowly over five to seven seconds at an angle of 45 degrees into fatty area of anterior thigh or abdomen every 12 to 14 weeks if more than 14 weeks elapse between injections rule out pregnancy prior to administration do not rub area after injection when switching from other hormonal
Contraceptives administer within dosing period seven days after taking last active peel removing patch or within the dosing period for intermuscular injection in intramuscular shake vial vigorously before preparing intramuscular dodo administer deep intermuscular into gluteal or deltoid muscle if period between injections is more than 14 weeks determine that
Patient is not pregnant before administering in patients with cancer intramuscular dose may initially be required weekly once stabilized intramuscular dose may be required only monthly explain the dose schedule to the client and extract patient to take medication at the same time each day take these doses as soon as remembered but do not double those advice
Patients receiving me for menstrual dysfunction to anticipate withdrawal bleeding stay to seven days after discontinuing medication advice patient to keep a one month supply of myself available at all times instruct patient correct method of monthly breast self-examination increased breast tenderness may occur advice patient the gingival bleeding may occur a
Patient to use good oral hygiene and to receive regular dental care and examination advice patient that i may cause melasma the brown patches of discoloration on face when patient is exposed to sunlight advise patient to avoid sun exposure and to wear sunscreen or protective clothing when outdoors is your patient to notify healthcare professional if menstrual
Period is missed or if pregnancy is suspected patient should not attempt conception for three months after discontinuing medication in order to decrease risk to fatus emphasize the importance of routine follow-up physical examination including bp breast abdomen and pelvic exams papa nikolao smears or pap smears every six to 12 months and lastly advice patient
To maintain adequate amount of dietary calcium and vitamin d to help prevent bone loss the after is the nurse must evaluate or check the desired outcomes of the joint therapy next is to check if the patient if she is having regular menstrual periods evaluate if there is a decrease in endometrial hyperplasia in post-menopausal woman receiving concurrent estrogen
And you should evaluate a drug has a control to the spread of endometrial or renal cancer lastly if the tract is a complete effect for the prevention of pregnancy so guys that’s all for today’s vlog i am the attractive progesterone drug detox productive system i hope you learned something thank you for watching bye
Transcribed from video
MEDROXYPROGESTERONE by Balahay and Cala By Batch Kunzite
